Genmab's Darzalex passes Phase III MM test

Genmab A/S (CSE:GEN) said an interim analysis of the Phase III Castor trial showed that Darzalex daratumumab met the primary endpoint of improving progression free survival (PFS) in relapsed or refractory multiple myeloma patients (p≤0.0001). Genmab's partner, the Janssen Biotech unit of Johnson & Johnson (NYSE:JNJ), will stop the trial early.

The study evaluated PFS in about 490 patients receiving Velcade bortezomib and dexamethasone alone or in combination with Darzalex. Genmab said the human IgG1k against CD38 showed a tolerable safety profile. ...